Short communication: Lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients

AIDS Research and Human Retroviruses

Volumn 28, Issue 8, 2012, Pages 776-779

  Hirano, Atsushi ^a,b   Ikemura, Kenji ^c   Takahashi, Masaaki ^a   Shibata, Masaaki ^a   Amioka, Katsuo ^c   Nomura, Toshiharu ^a   Yokomaku, Yoshiyuki ^a   Sugiura, Wataru ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KINJO GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; LAMIVUDINE PLUS ZIDOVUDINE; RALTEGRAVIR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC CORRELATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRROLIDINONES; YOUNG ADULT;

EID: 84864247327     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0231     Document Type: Article

References (13)

1. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, and Miller MD: Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-650.
2. Cahn P and Sued O: Raltegravir: A new antiretroviral class for salvage therapy. Lancet 2007;369:1235-1236.
3. Croxtall JD, Lyseng-Williamson KA, and Perry CM: Raltegravir. Drugs 2008;68:131-138.
4. Evering TH and Markowitz M: Raltegravir (MK-0518): An integrase inhibitor for the treatment of HIV-1. Drugs Today (Barc) 2007;43:865-877.
5. Department of Health and Human Services: Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents inHIV-1-infected adults and adolescents. 2011;1-166. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed September 1, 2011.
6. Pharmacogenomics Laboratory: Canada Research Chair in Pharmacogenomics www.pharmacogenomics.pha.ulaval.ca/ sgc/.
7. Huang YY, Huang MJ, Yang SS, Teng HC, and Huang CS: Variations in the UDP-glucuronosyltransferase 1A1 gene for the development of unconjugated hyperbilirubinemia in Taiwanese. Pharmacogenomics 2008;9:1229-1235.
8. Palomaki GE, Bradley LA, Douglas MP, Kolor K, and Dotson WD: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009;11:21-34.
9. Ehmer U, Lankisch TO, Erichsen TJ, Kalthoff S, Freiberg N, Wehmeier M, Manns MP, and Strassburg CP: Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1. 28. J Mol Diagn 2008; 10:549-552.
10. Takahashi M, Konishi M, Kudaka Y, Okumura N, Hirano A, Terahata N, Banno K, and Kaneda T: A conventional LCMS method developed for the determination of plasma raltegravir concentrations. Biol Pharm Bull 2008;31:1601-1604.
11. Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, De- Lepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdori F, Greenberg H, Stone JA, Wagner JA, and Iwamoto M: Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther 2009;85:623-627.
12. Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RMW, Wagner JA, and Iwamoto M: Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008;52:4228-4232.
13. Neely M, Decosterd L, Fayet A, Lee JS, Margol A, Kanani M, di Iulio J, von Schoen-Angerer T, Jelliffe R, and Calmy A: Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother 2010;54:4619-4625.